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Fifteen drug-free patients with early to midstage Huntington’s disease were evaluated with quantitative neurological 
examinations, scales for functional capacity, computed tomographic (CT) scans, and positron emission tomographic 
(PET) scans of ‘*F-2-fluoro-2-deoxyglucose ( ‘*F-FDG) uptake. All patients had abnormal indices of caudate metabolism 
on PET scanning, whereas in patients with early disease indices of putamen metabolism and CT measures of caudate 
atrophy were normal. Indices of caudate metabolism correlated highly with the patients’ overall functional capacity ( r  
= 0.906; p < 0.001) and bradykinesidrigidity (r = -0.692; p < 0.01). Indices of putamen metabolism correlated 
highly with motor functions: chorea ( r  = - 0.841; p < 0.01), oculomotor abnormalities (r = - 0.849; p < 0.01), and fine 
motor coordination (r = - 0.866, p < 0.01). Indices of thalamic metabolism correlated positively with dystonia (r = 
0.559; p < 0.05). The data suggest that PET scanning with “F-FDG is a sensitive measure of brain dysfunction in 
Huntington’s disease and that basal ganglia metabolism is highly correlated with the overall functional capacity of 
individual patients and with the degree of their motor abnormalities. 
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Huntington’s disease (HD) is a dominantly inherited 
neurodegenerative disorder characterized by progres- 
sive cognitive and motor deterioration. The clinical 
features and natural history of the disease have been 
carefully evaluated and defined. Early neurological 
signs include chorea, decreased fine motor coordina- 
tion, and slowed saccadic eye movements [7, 11, 16, 
26-29, 351. Later signs include dysarthria, rigidity, 
bradykinesia, and dystonia [7, 11, 26-28, 351. With 
progression, the patient’s ability to perform activities 
of daily living declines {4, 5, 26, 27, 291. A number of 
standardized rating scales have been designed to quan- 
tify the motor and functional capacities in this disorder 
Pathologically, HD is characterized by marked 
neuronal loss in the caudate nucleus and putamen, 
with coexistent gliosis and astrocytic proliferation [3, 
15, 331. Little or no cortical abnormality has been ob- 
served {333. The globus pallidus and thalamus are 
mildly affected as is the cerebellum {3, 6, 157. 
With the advent of positron emission tomographic 
17,26,27,29,351. 
(PET) techniques for studying brain metabolism, it has 
been possible to investigate HD patients at various 
stages of their illness to determine the relationship be- 
tween brain metabolism and the neurological features 
of the disease [12-14, 231. Studies with PET have 
shown a marked reduction of caudate metabolism in 
patients with early HD who exhibit little or no atrophy 
as measured by computed tomography (CT) [13}. 
These earlier studies investigated patients treated with 
various pharmacological agents and did not attempt to 
correlate specific neurological and behavioral findings 
with brain glucose metabolism. We observed 15 un- 
medicated HD patients who were evaluated carefully 
by clinical and neuropsychological testing. We present 
here our findings on the physiological aspects of the 
illness. Another report on the results of neuropsy- 
chological testing is in preparation [21. 
Methods 
Fifteen patients with adult-onset HD, as determined by fam- 
ily history and physical examination, were examined at least 
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1 month after discontinuation of any medications. Over a 2- 
day period, patients received: (1) a quantitative neurological 
evaluation conducted by two or more investigators using a 
previously designed scale 135); (2) an evaluation of func- 
tional capacity according to the Shoulson and Fahn scale 
{29); and (3) neuropsychometric testing (results to be re- 
ported separately 12)). In addition, each patient had a CT 
scan and PET scan using 18F-2-fluoro-2-deoxyglucose (“F- 
FDG). 
The 15 HD patients (ages 25 to 60 years; average ? SEM: 
40 * 3 years) were compared with 14 normal controls (ages 
25 to 65 years; average 5 SEM: 37 ? 3 years). Patients 
were in stages I, 11, or 111 of the disease as defined by the 
Shoulson and Fahn scale, a total functional capacity (TFC) 
scale that assesses the patient’s ability to be gainfully em- 
ployed, to handle financial and domestic responsib 
perform activities of daily living, and to be cared for at home 
129). It is a 13-point scale with 13 indicating normal and 0 
referring to patients who require total care. It is further sub- 
divided into five stages: stage I (TFC 13-11), stage I1 (TFC 
10-7), stage I11 (TFC 6-3), stage IV (TFC 2-l), and stage V 
(TFC 0). 
For PET studies, patients had an arterial line placed in the 
radial artery of one arm and an intravenous line in the other 
arm. I8F-FDG (5 to 10 mCi) was injected as an intraveous 
bolus while the patient was in a quiet, dimly lit room with 
minimal background noise, with eyes blindfolded and ears 
unplugged. Although sensory deprivation is known to affect 
glucose metabolism in normal subjects [IS}, these condi- 
tions were chosen because they were considered to provide 
the most reproducible scanning conditions among subjects. 
Plasma “F-FDG curves were determined for each patient. 
Repeated 0.5-ml arterial samples were drawn over the first 
45 minutes after injection according to the following pro- 
tocol: injection to 2 minutes, one sample every 5 seconds, 
then samples at 3,4,  5, 6, 7, 12, 17,22, 37, and 45 minutes. 
The scans were obtained on a Cyclotron Corporation PET 
4600A Scanner, which is a three-ring (2.2-cm center-to- 
center spacing), five-slice, 96-detectorhing tomograph. The 
spatial resolution is 11 mm in the X-Y plane (within a trans- 
axial slice) and 8.8 mm in the 2 plane (along the central axis 
of the scanner). Ten transaxial slices separated by approxi- 
mately 5.5 mm with an orientation parallel to the cantho- 
meatal line were obtained from the base of the cerebellum to 
the top of the caudate nucleus. An additional five slices sepa- 
rated by 11 mm were acquired to image the next 5 cm of 
brain. The local glucose metabolic rate (1CMRglc) for each 
region of brain was calculated according to previously de- 
scribed methods 122, 31) using updated rate constants 
{Mazziotta JC, personal communication, 1984). 
Data from each scan were analyzed by a standard tech- 
nique as described below. The slice corresponding to the 0- 
degree Section, No. 8 or No. 9 from the CT atlas of Matsui 
and Hirano 1171, was analyzed in detad from each patient. 
Cross-sectional histograms through (I) the caudate nucleus 
(halfway between the rostral edge of the thalamus and the 
frontal cortex anterior to the ventricles); (2) the putamen 
(halfway between the caudate cross-section and the rostral 
edge of the thalamus); and (3) the middle of the thalamus 
(Fig 1). By inspection of the cross-sectional histograms, the 
maximum glucose metabolic rate over the head of the cau- 
date was observed in all the normal controls and in most of 
the HD patients. Although caudate metabolism In some of 
the HD patients was quite low, the location of the shoulder 
on the cross-sectional histogram could be determined by cal- 
culating the second derivative of the curve (Fig 2). Although 
this method of determining caudate metabolism cannot cor- 
rect for alterations in partial volume, it was found to be more 
reproducible than values obtained from simple, visually 
guided region-of-interest (ROI) measurements. This method 
was also considered to be more accurate than the use of 
standardized ROI programs, which do not correct for the 
underlying caudate atrophy in HD. Values of caudate, puta- 
men, and thalamus metabolic activity were taken as an aver- 
age of data from a 1 x 3 pixel ROI (ROI = Z$X,! ICMRglc,,) 
on a 64 x 64 pixel matrix reconstruction of the PET scan 
data. Raw data from right and left cortex, caudate, putamen, 
and thalamus were averaged in 10 patients and 10 controls 
(Table 1). (Data from the first 5 HD patients and first 4 
controls were not included in this latter analysis because they 
were scanned prior to a series of modifications in our scanner 
that affected absolute but not relative measures of glucose 
metabolism.) The lack of metabolic change in HD cortex 
compared with controls suggested that normalization of the 
values of caudate, putamen, and thalamus to cortex at the 
same levels was valid for subsequent analyses. Normalization 
is frequently used in PET studies because it reduces the 
overall variability of the measures 113, 14, 23). Absolute 
measures of metabolism from caudate, putamen, and 
thalamus were normalized to the peak cortical activity (a 1 x 
3 pixel 111 mm2) ROI) determined on the same cross- 
sectional histogram (see Fig 1). The normalized values will be 
referred to as indices of metabolism. The ratio of caudate me- 
tabolism to putamen metabolism was also calculated for each 
patient. 
In this study, CT scans were evaluated using previously 
described techniques [I, 25, 30, 32). Both the frontal horn/ 
bicaudate diameter ratios (FWCC) and the bicaudate diame- 
ter/outer table diameter ratios (CUOT) at the level of the 
caudate were calculated as depicted in Figure 1. 
PET and CT scan data were obtained and recorded sepa- 
rately from the clinical information. Data from scans and the 
clinical evaluations were entered into a computer for analy- 
sis. The scan measurements were then compared between 
the controls and HD patients using t tests. The non- 
parametric clinical data were analyzed and compared to scan 
data and to each other using Spearman rank correlation 
coefficients. Parametric scan data were compared to other 
scan data using Pearson product-moment correlation 
coefficients. Data analysis was done using the Biomedical 
Program Statistical Software (Alphaville, CA). 
Results 
All HD patients had demonstrable PET abnormalities 
(Figs 2, 3). There were 5 stage I patients, 9 stage I1 
patients, and 1 stage I11 patient. Measurement of corti- 
cal metabolism at the level of the caudate, putamen, 
and thalamus in the HD patients did not differ 
significantly from that in controls (see Table 1). In HD 
patients as a population, the caudate and putamen met- 
abolic activity was significantly decreased compared 
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with controls. The thalamic metabolism in HD patients 
was not significantly different from control values, but 
when normalized to cortex as in Figure 1, thalamic/ 
cortex ratios were significantly higher in HD patients 
than they were in controls (1.06 t 0.14 standard devi- 
ations [SD] versus 0.94 t 0.12 SD; p < 0.02, Stu- 
dent's independent t test). 
Caudate and putamen indices of metabolism were 
highly correlated with the TFC of the patient (see Fig 
3, Table 2). In the earliest stages of the disease, the 
caudate index in the HD patients fell just below the 
lowest index of the control group, and as a group, the 
stage I patients (TFC = 13- 11) had significantly lower 
caudate indices than did the control group @ < 0.01). 
Putamen indices had a strong correlation with TFC, 
but in stage I patients the putamen indices did not 
differ significantly from those of the control group. 
Putamen indices for the stage I1 patients (TFC = 10- 
7 )  were clearly lower than those of controls (p < 0.01). 
The PET measures of caudate and putamen were cor- 
related very highly with each other, but not with the 
thalamic indices. There was also no correlation be- 
tween TFC and the thalamic indices of metabolism. 
The quantitative neurological measures (chorea, 
both at rest and during stress), dysdiadochokinesia 
(evaluated by rapid finger tapping as well as alternating 
supination and pronation of the hands), abnormalities 
of saccadic eye movements, bradykinesidrigidity, and 
dystonia were analyzed in detail (Table 3). Motor ab- 
normalities were highly correlated with each other, ex- 
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Fig  I .  Summary of positron emission tomographic and computed 
tomographic (CT) measures. Histograms of crofs-sectional meta- 
bolic data (A) were obtained through the caudate (B), putamen 
(C), and thahmus (0). Indices of caudate, putamen, and 
thalamic metabolism were calculated by determining the peak 
values of metabolic data through the structures in question 
(open circles) normalized to the peak cortical activity at the 
jame level (open triangles). (E) CT  measures were also made: 
CC = the intercaudate distance; OT = the distance between 
the outer tables of the skull at the level of the caudate; and FH 
= the distance between the tips of the frontal horns at the level 
of the caudate. (LCMRG = local cerebral metabolic rate for glu- 
cose; CD = caudate; CX = cortex; PU = putamen; TH = 
thalamus.) 
F ig  2. Examples o f  computed tomographic (CT)  ([eft) and posi- 
tron emission tomographic (PET) (middle) scans on a series of 
cases ranging from n o w 1  (A) to stage III Huntington's disease 
(0). The C T  and PET scans were taken at a level midway 
through the caudate and putamen. To the right o f  each PET 
scan is the cross-sectional histogram of metabolic data taken 
through the caudate (see legend for Figure 1 for method) as 
shown by the arrow1 on the PET s i m s .  Note the decrease in 
caudate metabolism as the disease advances. (LCMRG = local 
cerebral metabolic rate for glucose; TFC = total functional ca- 
pacity, see text for description of staging.) 
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Table 1. Glucose Metabolism in Cortex, Basal Ganglia, 
and Thalamus of Huntington's Disease Patients 
and Age-Matched Controlsa 
. . r = 0.84 
' A t  
a .  
0 .  
Regionb 
Cerebral cortex 
At level of caudate 
At level of putamen 





(mg/min/100 gm tissue ~fr SD) 
Huntington's 
Controls Disease 
7.1 ? 1.8 6.5 ? 1.5 
6.5 f 1.8 6.3 f 1.4 
6.6 f 1.4 6.5 f 1.2 
7.1 Ifr 1.2 2.8 2 1.G' 
7.1 t 1.8 3.7 f 1.7' 
6.1 t 1.7 7.0 f 1.2 
"Values are from 10 controls and 10 Huntington's disease patients. 
bValues from each area represent the raw data obtained from 1 X 3 
pixel (11 mm2) regions of interest as described in Figure 1. 
'p  < 0.001 by two-tailed independent Student's t test. 
ICMRglc = local cerebral metabolic rate for glucose; SD = standard 
deviation. 
cept for dystonia which did not relate to abnormal eye 
movements or bradykinesidrigidity. Abnormalities on 
the neurological examination were also highly cor- 
related with alterations in basal ganglia metabolism 
(see Table 2). Caudate and putamen indices were cor- 
related significantly with TFC and all motor functions 
except dystonia. Thalamic indices were correlated only 
with dystonia. 
Since PET and CT measures were so highly cor- 
related with each other, multiple linear regression anal- 
yses were used to determine the relative contribution 
of the metabolic and CT data to the functional and 
neurological features of the patient. The caudate index 
of metabolism accounted for 85.3% of the variation in 
TFC (F[1,12) = 69.6), with the FWCC ratio account- 
ing for an additional 4.0% of the variability (F[2,11) = 
47.6) and the caudate/putamen ratio accounting for 
another 3.0% (F[3,10) = 42.1). For neurological mea- 
sures, the putamen index accounted for most of the 
variability in chorea, dysdiadochokinesia, and abnor- 
mal eye movements; the caudate index accounted for 
the variability of bradykinesidrigidity; the thalamus 
and putamen indices together accounted for the vari- 
ability of dystonia. 
CT scan measures of the CC/OT ratio correlated 
with TFC, oculomotor abnormalities, dysdiadocho- 
kinesia, and resting chorea. CC/OT ratios were signifi- 
cantly correlated with PET caudate and putamen in- 
dices (Table 4). The CT scan measure of the FWCC 
ratio was not significantly correlated with TFC or 
any of the neurological signs, but was correlated with 
caudate and thalamic metabolism. 
:D,cq: . :';.;
0 .  
13 12 11 10 0 8 7 8 
TOTAL FUNCTIONAL CAPACITY 
TOTAL FUNCTIONAL CAPACITY 
I 
13 12 1 1  10 0 8 7 8 
TOTAL FUNCTIONAL CAPACITY 
Fig 3. Plots of metabolic and computed tomographic (CT) data 
in a group of controls (open circles) and Huntington's disease 
(HD) patients (closed circles). There is a high degree of correla- 
tion between functional capacity and both positron emission to- 
mography (PET) and CT measures. PET measures through cau- 
A t e  (top) distinguish the early HD cases more accurately from 
the controls than do the putamen measures (midle). Numbers 
indicate the Spearman correlation roefficients (r) of the data. 
Discussion 
Our data indicate that basal ganglia metabolism is 
clearly abnormal in HD and that the degree of meta- 
bolic abnormality is correlated both with the patients' 
overall TFC as well as with their neurological signs and 
symptoms. The TFC scale used in this study has been 
validated in prior studies of CT measures [30J and in 
studies of the clinical progression of the disease [26, 
27, 351. This scale seems to be very sensitive to mea- 
sures of early progression in the illness. Our study 
confirms previous CT studies of HD 125, 30, 321 and 
provides evidence that metabolic measures in caudate 
are even more sensitive in early disease than are CT 
measures. Caudate metabolism is particularly sensitive 
to functional decline since even patients with the ear- 
liest forms of the disease had caudate metabolism be- 
low that of the lowest normal subject examined. In 
these patients with early HD, CT measures were nor- 
mal. The presence of a relationship between functional 
capacity and caudate metabolism is further established 
by the strong correlation between TFC and verbal 
learning and memory, cognitive efficiency, and years 
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Table 2. Speamzan Rank Cowelation Coefficients for the Relationships between Neurological Signs, 
PET Measures of ICMRgkc, and CT Measures of Atrophy 
PET Measure 
CT Measure (n = 14) 
FWCC Clinical Sign Caudate Putamen Putamen Thalamus CC/OT 
Total functional capacity (n = 1 5 )  0.906' 0.836' 0.425 0.137 - 0.670" 0.360 
Chorea at rest (n = 1 5 )  -0.761' -0.841' -0.301 0.000 0.593" -0.179 
Chorea with stress (n = 1 5 )  - 0.635" - 0.798' -0.055 0.158 0.413 0.026 
Dysdiadochokinesia (n = 15)  -0.776' - 0.866' - 0.248 - 0.01 1 0.676b -0.339 
Slowed saccades (n = 12) - 0.745b - 0.849' -0.217 - 0.004 0.593" - 0.366 
Dystonia (n = 1 5 )  -0.235 - 0.497 0.062 0.559" 0.204 - 0.305 
Bradykinesidrigidity (n = 1 5 )  - 0.692b - 0.690b -0.138 -0.158 0.514 -0.276 
Caudate/ 
Age (n = 1 5 )  -0.018 0.098 -0.316 0.070 0.173 0.102 
"p < 0.05; 'p  < 0.01; ' p  < 0.002. 
PET = positron emission tomography; ICMRglc = local cerebral metabolic rate for glucose; CT = computed tomography; CC/OT = bicaudate 
diametedouter table diameter ratio; FWCC = frontal hordbicaudate diameter ratio. 
Table 3 .  Spearman Rank Cowelation Coefficients for the Relutionships between Various Motor Signs and Total Functional Capacity 
Chorea 
With Bradykinesid Slowed 
Motor Signs At Rest Stress Dystonia Rigidity Saccades Dysdiadochokinesia 
Total functional capacity -0.841b -0.791b -0.444 - 0.84gb - 0.907b - 0.86gb 
Chorea at rest 0.938b 0.63 1" 0.696" 0.7 14" 0.805b 
Chorea with stress 0.696" 0.733b 0.679" 0.832b 
Dystonia 0.358 0.454 0.62 1" 
Bradykinesidrigidity 0.843b 0.790b 
Slowed saccades 0.860b 
"p < 0.05; "p < 0.002. 
Table 4 .  Peanon Product-Moment Correlation Coefficients for the Relationships between Various 
Positron Emission Tomographic and Computed Tomographic Measures 
Putamen Thalamus 
Measure Metabolism Metabolism CCIOT FWCC 













"p < 0.05. 
CC/OT = bicaudate diametedouter table diameter ratio correlation coefficient; FWCC = frontal hordbicaudate diameter ratio. 
bp < 0.002. 
after diagnosis. Also, there is a strong correlation be- 
tween caudate metabolism and learning and memory 
127. 
The fact that in early HD caudate metabolism is 
affected more dramatically than is putamen metabo- 
lism reinforces the pathological information on pa- 
tients with early disease that the disorder begins in the 
caudate nucleus (specifically the dorsal medial areas of 
caudate) and then progresses to the putamen 1337. 
Putamen metabolism is not as sensitive since there was 
overlap between stage I patients and the control group 
in this measure. That caudate and putamen metabolism 
were only mildly reduced in patients with early disease 
suggests that either the symptoms of HD begin soon 
after the onset of neuronal damage or that compensa- 
tory properties maintain or even increase metabolic 
activity in the remaining basal ganglia neurons. 
Caudate metabolism was not as significantly cor- 
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related with motor abnormalities as was putamen me- 
tabolism. However, caudate metabolism was cor- 
related very highly with putamen metabolism (Y = 
$0.786; p < 0.002), and so the relative contributions 
of each are difficult to discern. Since the caudate nu- 
cleus receives its major inputs from association cortex 
and not from primary motor and sensory cortex [S] ,  
the lower correlations of caudate metabolism with 
motor variables are noteworthy. Thus, decreased cau- 
date metabolism would likely reflect primarily impair- 
ment of cognitive and integrative functions and be less 
indicative of pure motor dysfunction. The high corre- 
lation of caudate indices of metabolism with TFC sug- 
gests that the cognitive dysfunction in HD influences 
TFC to a major extent. The disturbance in cognition 
may subserve a lowering of TFC. New learning cor- 
related highly with both TFC and caudate metabolism 
12). However, there was a lack of correlation between 
cognitive and motor measurements [2].  Furthermore, 
multiple linear regression analyses suggest that caudate 
metabolism was the most important feature in deter- 
mining TFC. 
The high correlation of putamen metabolism with 
motor abnormalities may reflect the fact that the puta- 
men receives input from sensory and motor cortex C81. 
Multiple regression analyses further support this con- 
clusion since putamen indices explained most of the 
variability in the motor features except for dystonia 
and bradykinesidrigidity. Thus, dysfunction of puta- 
men neurons would likely lead to poor motor coor- 
dination. 
Thalamic activity was correlated with dystonia, and it 
is of interest that metabolic activity in this area was 
increased in the HD patients as a group compared with 
controls. Neuroanatomical and neurochemical infor- 
mation suggests that the caudate and putamen output 
cells project to the medial and lateral globus pallidus 
and substantia nigra pars reticulata IS}. These pro- 
jections are primarily inhibitory and y-aminobutyric 
acid-ergic (GABAergic) 120, 341. The medial globus 
pallidus and substantia nigra pars reticulata neurons are 
also inhibitory and GABAergic, and project to the 
thalamus [20, 341. Thus the increased thalamic metab- 
olism in HD patients may represent a disinhibition of 
pallidothalamic and nigrothalamic pathways. Our data 
would suggest that excessive input to the thalamus 
from the globus pallidus and substantia nigra pars re- 
ticulata may contribute to dystonic motor abnor- 
malities. We plan a future study of rigid and dystonic 
juvenile patients. 
There have been other studies of PET scanning in 
HD [12-14, 19, 21, 231. As previously described, we 
found a significant decrease in the glucose metabolic 
rate in the basal ganglia of patients with early disease 
while there was little or no caudate atrophy observed 
on CT scans. However, unlike previous authors 112, 
141, we found less difference between the glucose 
metabolic rate of our patients with early disease and 
that of controls. In addition, we observed strong direct 
correlations between metabolic indices and the degree 
of functional or  motor abnormalities in the patients. 
Others have studied at-risk persons and found altered 
metabolism in about one half of the subjects 112, 131. 
Some of these patients have gone on to develop HD 
112). We are currently studying 40 at-risk persons pro- 
spectively but have found only minimal caudate 
changes to date. The studies in at-risk persons will help 
define further the relationship between the earliest 
metabolic changes and motor and cognitive decline. 
In summary, PET measures of basal ganglia metabo- 
lism have reinforced our knowledge of basal ganglia 
anatomy, physiology, and pathology and suggest that 
such measures will be useful indicators of functional 
and clinical decline in HD patients. If subsequent at- 
risk studies confirm that there are significant metabolic 
changes before the onset of symptoms, then prophy- 
lactic therapy in conjunction with PET scanning may 
provide a useful measure of therapeutic agents. Such 
measures will be particularly important since the new 
data describing a DNA marker linked to the HD gene 
will soon allow the diagnosis of HD in presymptomatic 
patients [9, lo]. 
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